Chimerix, Inc. (CMRX) - Quarterly EPS earnings growth

Official company branding of Chimerix (CMRX)

Chimerix, Inc. develops molecular therapies for rare pathologies and malignant neoplasms. The company's prospects are based on trials of the ONC201 inhibitor against gliomas and the potential for acquisition by industry behemoths. Stable compound supplies are guaranteed by secured contracts. Quarterly EPS dynamics demonstrate financial stability, where the value of -24.30 reflects this current status of business profitability.

Chimerix (CMRX) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 04/26/2025

Analytical breakdowns for Chimerix, Inc.

- market value and analyst target forecast:
Price Chart Chimerix|CMRX - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Chimerix, Inc|CMRX - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Chimerix|CMRX - Total Stockholders' Equity|Market Value to Book Value Ratio chimerix.com|CMRX - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Chimerix, Inc.|CMRX - Long-Term Liabilities to Capital|Short-Term Debt to Capital Chimerix, Inc.|CMRX - Company Total Indebtedness|Debt to Book Value Chimerix, Inc|CMRX - Long-Term Debt|Company Current Liabilities Chimerix|Quick Liquidity Indicator chimerix.com
- earnings and market multiples details:
CMRX - Profit After Payment of Taxes|Projected Future Earnings Chimerix, Inc.|CMRX - Company Value to Net Income|Forward P/E Multiple Chimerix, Inc|CMRX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Chimerix, Inc|CMRX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Chimerix|CMRX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months chimerix.com|CMRX - Earnings per share trend in current year|Expected earnings per share growth for next year Chimerix, Inc.
Fundamental company analysis:Chimerix, CMRX
Manufactured product of Chimerix Inc

Quarterly EPS growth measures the dynamics of net profit per share, allowing investors to assess the speed of business scaling without reporting gaps. By analyzing the relative quarterly change in EPS, one can identify the critical impact of high capital burn rates and clinical failure risks at Chimerix, Inc. (CMRX) on final profitability amid a dependence on government funding.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (cellectar.com)|BioLineRx - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma Ltd)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kazia Therapeutics Limited (KZIA)|Year-over-year earnings per share growth for the last twelve months Silexion Therapeutics Corp.|NCNA: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com